About: Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential
Creator	Krampera, Mauro Weiss, Daniel Galipeau, Jacques Khoury, Maroun Leblanc, Katarina Martin, Ivan Nolta, Jan Phinney, Donald Rocco, Patricia Viswanathan, Sowmya
source	Elsevier; PMC
abstract	The serious consequences of the global COVID-19 pandemic have prompted a rapid gobal response to develop effective therapies that can lessen disease severity in infected patients. Cell-based approaches, primarily using mesenchymal stromal cells (MSCs), have demonstrated a strong safety profile and possible efficacy in patients with the acute respiratory distress syndrome (ARDS), but whether these therapies are effective for treating respiratory virus-induced ARDS is unknown. According to the WHO ICTRP and the NIH clinicaltrials.gov databases, 27 clinical investigations of MSC-based cell therapy approaches have begun in China since the onset of the COVID-19 outbreak, as well as a growing number of academic and industry trials elsewhere. Several recent published reports have suggested potential efficacy; however, the available data presented is either anecdotal or from incomplete, poorly controlled investigations. Therefore, while there may be a potential role for MSCs and other cell-based therapies in treatment of COVID-19, these need to be investigated in a rationally designed, controlled approach if safety and efficacy are to be demonstrated accurately. We urge that the field proceeds by finding balance between swift experimentation and communication of results, and scientifically coherent generation and analysis of clinical data.
has issue date	2020-04-17(xsd:dateTime)
bibo:doi	10.1016/j.jcyt.2020.04.089
has license	no-cc
sha1sum (hex)	1c1aff9ccfa539a96b8ea4d09d1bee1707a58e7f
schema:url	https://doi.org/10.1016/j.jcyt.2020.04.089
resource representing a document's title	Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential
has PubMed Central identifier	PMC7163352
schema:publication	Cytotherapy
resource representing a document's body	covid:1c1aff9ccfa539a96b8ea4d09d1bee1707a58e7f#body_text
is schema:about of	named entity 'Investigations' named entity 'COVID-19 PANDEMIC' named entity 'patients' named entity 'Cell-Based Therapies' named entity 'patient outcomes' named entity 'co-occurring' named entity 'immunotherapy' named entity 'critically ill patients' named entity 'pathogenesis' named entity 'ACE2' named entity 'inclusion and exclusion criteria' named entity 'North America' named entity 'COVID19' named entity 'clinical investigations' named entity 'Mesoblast' named entity 'World Health Organization' named entity 'infusion' named entity 'SARS-CoV-2' named entity 'GCP' named entity 'control patients' named entity 'saline' named entity 'RNAseq' named entity 'cell culture' named entity 'extravascular' named entity 'informed consent' named entity 'WHO' named entity 'U.S. Food and Drug Administration' named entity 'clinical trials' named entity 'COVID' named entity 'titer' named entity 'superinfection' named entity 'Europe' named entity 'evidence-based' named entity 'comorbidities' named entity 'therapeutic approaches' named entity 'open-label' named entity 'COVID' named entity 'clinical trials' named entity 'H7N9' named entity 'case report' named entity 'ARDS' named entity 'gene' named entity 'COVID' named entity 'ISSCR' named entity 'clinical testing' named entity 'etiologies' named entity 'long-term' named entity 'ARDS' named entity 'infusion' named entity 'clinical trials' named entity 'ICU' named entity 'coagulation' named entity 'COVID' named entity 'IL-1' named entity 'cell-based' named entity 'COVID' named entity 'International Society for Stem Cell Research' named entity 'Mesoblast' named entity 'Pluristem' named entity 'protein expression' named entity 'ARDS' named entity 'ARDS' named entity 'randomization' named entity 'infection' named entity 'COVID' named entity 'Maroun Khoury' named entity 'TMPRSS2' named entity 'respiratory diseases' named entity 'clinical research' named entity 'coronavirus' named entity 'health care providers' named entity 'treatment groups' named entity 'COVID' named entity 'ARDS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software